Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug targets for COVID-19 therapeutics: Ongoing global efforts
Ambrish Saxena
Journal of Biosciences (2020) Vol. 45, Iss. 1
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery
Muhammed Tılahun Muhammed, Esin Aki
Letters in Drug Design & Discovery (2022) Vol. 21, Iss. 3, pp. 480-495
Closed Access | Times Cited: 84
A Global Picture: Therapeutic Perspectives for COVID-19
Vivek P. Chavda, Carron Kapadia, Shailvi Soni, et al.
Immunotherapy (2022) Vol. 14, Iss. 5, pp. 351-371
Open Access | Times Cited: 73
The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies
Anastassios C. Papageorgiou, Imran Mohsin
Cells (2020) Vol. 9, Iss. 11, pp. 2343-2343
Open Access | Times Cited: 87
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
Uttpal Anand, Shweta Jakhmola, Omkar Indari, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 78
Artificial Intelligence in Surveillance, Diagnosis, Drug Discovery and Vaccine Development against COVID-19
Gunjan Arora, Jayadev Joshi, Rahul Shubhra Mandal, et al.
Pathogens (2021) Vol. 10, Iss. 8, pp. 1048-1048
Open Access | Times Cited: 73
Therapeutic monoclonal antibodies for COVID-19 management: an update
Vivek P. Chavda, Riddhi Prajapati, Disha Lathigara, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 6, pp. 763-780
Closed Access | Times Cited: 53
Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity
Ying Li Weng, Shiv Rakesh Naik, Nadia Dingelstad, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 52
Lead Discovery of SARS-CoV-2 Main Protease Inhibitors through Covalent Docking-Based Virtual Screening
Giorgio Amendola, Roberta Ettari, Santo Previti, et al.
Journal of Chemical Information and Modeling (2021) Vol. 61, Iss. 4, pp. 2062-2073
Closed Access | Times Cited: 48
The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2
Devendra Singh Negi, Irshad Ahmad
European Journal of Medicinal Chemistry (2021) Vol. 213, pp. 113157-113157
Open Access | Times Cited: 45
Pharmacological Significance of Hesperidin and Hesperetin, Two Citrus Flavonoids, as Promising Antiviral Compounds for Prophylaxis Against and Combating COVID-19
Pawan K. Agrawal, Chandan Agrawal, Gerald Blunden
Natural Product Communications (2021) Vol. 16, Iss. 10
Open Access | Times Cited: 44
In silico evaluation of food‐derived carotenoids against SARS‐CoV ‐2 drug targets: Crocin is a promising dietary supplement candidate for COVID ‐19
Somdutt Mujwar, Lei Sun, Özkan Fidan
Journal of Food Biochemistry (2022) Vol. 46, Iss. 9
Open Access | Times Cited: 37
Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing
Özkan Fidan, Somdutt Mujwar, Mateusz Kciuk
Molecular Diversity (2022) Vol. 27, Iss. 1, pp. 463-475
Open Access | Times Cited: 35
Targeting the SARS-CoV-2-spike protein: from antibodies to miniproteins and peptides
Sebastian Pomplun
RSC Medicinal Chemistry (2020) Vol. 12, Iss. 2, pp. 197-202
Open Access | Times Cited: 46
Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and In Vitro Study
Souvik Banerjee, Shalini Yadav, Sourav Banerjee, et al.
Journal of Chemical Information and Modeling (2021) Vol. 61, Iss. 11, pp. 5469-5483
Closed Access | Times Cited: 34
Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment
Zemene Demelash Kifle, Akeberegn Gorems Ayele, Engidaw Fentahun Enyew
Journal of Environmental and Public Health (2021) Vol. 2021, pp. 1-11
Open Access | Times Cited: 33
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens
Henry O’Donnell, Tia A. Tummino, Conner Bardine, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 23, pp. 17530-17539
Open Access | Times Cited: 33
Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic
Dimitriοs Vlachakis, Eleni Papakonstantinou, Τhanasis Mitsis, et al.
Food and Chemical Toxicology (2020) Vol. 146, pp. 111805-111805
Open Access | Times Cited: 37
COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus
Vladímir V. Kouznetsov
European Journal of Medicinal Chemistry (2020) Vol. 203, pp. 112647-112647
Open Access | Times Cited: 32
Inhibitory Activity of Flavonoid Scaffolds on SARS-CoV-2 3CLpro: Insights from the Computational and Experimental Investigations
Nopawit Khamto, Kraikrit Utama, Panida Boontawee, et al.
Journal of Chemical Information and Modeling (2024) Vol. 64, Iss. 3, pp. 874-891
Closed Access | Times Cited: 4
Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications
Biswajit Naik, Venkata Satish Kumar Mattaparthi, Nidhi Gupta, et al.
Journal of Biomolecular Structure and Dynamics (2021) Vol. 40, Iss. 19, pp. 9543-9567
Open Access | Times Cited: 25
Roles of existing drug and drug targets for COVID-19 management
Akeberegn Gorems Ayele, Engidaw Fentahun Enyew, Zemene Demelash Kifle
Metabolism Open (2021) Vol. 11, pp. 100103-100103
Open Access | Times Cited: 25
Importance of glutamine 189 flexibility in SARS-CoV-2 main protease: Lesson learned from in silico virtual screening of ChEMBL database and molecular dynamics
Mohamed A. Said, Amgad Albohy, Mohamed A. Abdelrahman, et al.
European Journal of Pharmaceutical Sciences (2021) Vol. 160, pp. 105744-105744
Open Access | Times Cited: 24
Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review
Madhusudan Goyal, Nisha Tewatia, Hemlata Vashisht, et al.
Journal of Infection and Public Health (2021) Vol. 14, Iss. 7, pp. 910-921
Open Access | Times Cited: 23
Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion
Xiongfei Tian, Ling Shen, Pengfei Gao, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 16
Severe acute respiratory syndrome Coronavirus-2 GenoAnalyzer and mutagenic anomaly detector using FCMFI and NSCE
Shivendra Dubey, Dinesh Kumar Verma, Mahesh Kumar
International Journal of Biological Macromolecules (2023) Vol. 258, pp. 129051-129051
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top